Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

A pivotal phase 2/3 trial of CB03-154, an oral potassium channel opener targeting motor neuron hyperexcitability in ALS, has completed enrollment. The 255-patient, China-based study will test three doses against placebo over 39 weeks, with functional decline as the primary endpoint. Topline results are expected in Q3 2027, and positive data could support a conditional approval filing in China.
Zhimeng Biopharma has wrapped up patient enrollment for its pivotal phase 2/3 trial of CB03-154, an oral KCNQ2/3 potassium channel opener being tested in people with amyotrophic lateral sclerosis (ALS) — a disease that still has no therapy capable of meaningfully reversing progression. The trial enrolled 255 adults across 15 sites in China, randomizing participants to one of three daily doses (5 mg, 10 mg, or 15 mg) or placebo for 39 weeks, with an optional open-label extension to follow.
The drug's mechanism targets neuronal hyperexcitability — the tendency of motor neurons in ALS to fire more readily than normal, which is thought to drive neurodegeneration. CB03-154 builds on the science behind ezogabine, an earlier KCNQ2/3 opener that showed biological activity in ALS but was hampered by a short treatment window, high dropout rates, and safety concerns. CB03-154 is designed to be more selective and better tolerated.
By the Numbers:
Why it matters: ALS remains one of the most devastating and treatment-resistant neurological diseases. A well-powered trial targeting a biologically validated mechanism — with a cleaner safety profile than its predecessor — could mark a meaningful step forward for patients who currently have very limited options.